User profiles for Preethi Subramanian

Preeti Subramanian

- Verified email at brightfocus.org - Cited by 1940

Dr. Preethi Subramanian

- Verified email at apu.edu.my - Cited by 105

Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the big ten COVID-19 cardiac registry

…, S Smart, J Mayercin-Johnson, P Subramanian… - JAMA …, 2021 - jamanetwork.com
Importance Myocarditis is a leading cause of sudden death in competitive athletes. Myocardial
inflammation is known to occur with SARS-CoV-2. Different screening approaches for …

[HTML][HTML] Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2

BJ Pettus, A Bielawska, P Subramanian… - Journal of Biological …, 2004 - ASBMB
Recently, we demonstrated that ceramide kinase, and its product, ceramide 1-phosphate (Cer-1-P),
were mediators of arachidonic acid released in cells in response to interleukin-1β …

The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors

SG Payne, CA Oskeritzian, R Griffiths, P Subramanian… - Blood, 2007 - ashpublications.org
FTY720 is a potent immunomodulator drug that inhibits the egress of lymphocytes from
secondary lymphoid tissues and thymus. FTY720 is phosphorylated in vivo by sphingosine …

[HTML][HTML] Ceramide-1-phosphate binds group IVA cytosolic phospholipase a2 via a novel site in the C2 domain

RV Stahelin, P Subramanian, M Vora, W Cho… - Journal of Biological …, 2007 - ASBMB
Previously, ceramide-1-phosphate (C1P) was demonstrated to be a potent and specific activator
of group IV cytosolic phospholipase A 2 α (cPLA 2 α) via interaction with the C2 domain. …

[HTML][HTML] Solving neurodegeneration: common mechanisms and strategies for new treatments

…, MV Canto-Soler, JG Flanagan, P Subramanian… - Molecular …, 2022 - Springer
Across neurodegenerative diseases, common mechanisms may reveal novel therapeutic
targets based on neuronal protection, repair, or regeneration, independent of etiology or site of …

[HTML][HTML] Ceramide 1-phosphate acts as a positive allosteric activator of group IVA cytosolic phospholipase A2α and enhances the interaction of the enzyme with …

P Subramanian, RV Stahelin, Z Szulc… - Journal of Biological …, 2005 - ASBMB
Previous findings from our laboratory have demonstrated that cPLA 2 α is directly activated
by the emerging bioactive sphingolipid, ceramide 1-phosphate (C-1-P) (1). In this study, a …

3D hologram in futuristic classroom: A review

…, MM Chong, P Subramanian - … of Engineering and …, 2019 - pen.ius.edu.ba
Holography is a photographic method that records the light dispersed from a body and then
produces a realistic image identified as three-dimensional Holograms. The hologram reflects …

[HTML][HTML] Consensus recommendation for mouse models of ocular hypertension to study aqueous humor outflow and its mechanisms

…, A Soundararajan, P Subramanian… - … & visual science, 2022 - iovs.arvojournals.org
Due to their similarities in anatomy, physiology, and pharmacology to humans, mice are a
valuable model system to study the generation and mechanisms modulating conventional …

[HTML][HTML] Ceramide 1-phosphate is required for the translocation of group IVA cytosolic phospholipase A2 and prostaglandin synthesis

NF Lamour, P Subramanian, DS Wijesinghe… - Journal of Biological …, 2009 - ASBMB
Little is known about the regulation of eicosanoid synthesis proximal to the activation of
cytosolic phospholipase A 2 α (cPLA 2 α), the initial rate-limiting step. The current view is that …

[HTML][HTML] Substrate specificity of human ceramide kinase

DS Wijesinghe, A Massiello, P Subramanian… - Journal of lipid …, 2005 - ASBMB
Previous studies in our laboratory have established ceramide kinase (CERK) as a critical
mediator of eicosanoid synthesis. To date, CERK has not been well characterized in vitro. In …